BioWorld

Nov. 18, 2002

Confirmatory Phase III Prestara Protocol Submitted By Genelabs

Genelabs Technologies Inc. has laid the groundwork for a confirmatory Phase III trial of its lupus drug, Prestara, and said it expects to begin the trial before the end of the year. (BioWorld Today) Read More

NIH Awards Structural GenomiX Authority Over Protein Research

TransForm Pharmaceuticals, Weizmann Institute Align To Develop Better Malaria Drug

SuperGen Receives Approval For Supergeneric Mitozytrex

Medicon Valley Developing R&D Capabilities In Four Key Areas

ViroLogic Plans Cuts While It Raises $10M, Deals With Pfizer

Other News To Note

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...